• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Avedro acquires assests from IROC Innocross AG

Article

Avedro Inc. recently announced that it has purchased the assets of IROC Innocross AG, of Zug, Switzerland.

Boston-Avedro Inc. recently announced that it has purchased the assets of IROC Innocross AG, of Zug, Switzerland.

FDA seeking more info on Avedro’s corneal cross-linking NDA

IROC Innocross was the first company to commercialize a cross-linking device for the treatment of keratoconus and other corneal pathologies.

With this acquisition, Avedro’s platform of cross-linking technology now covers the entire spectrum of corneal cross-linking procedures, from treating corneal pathology with our UV-X devices and MedioCROSS riboflavin–to enhancing LASIK outcomes with our KXL System andVibeX riboflavin–to developing non-invasive refractive procedures with our advanced KXL II System.

Avedro will continue to work with key IROC Innocross suppliers MDP Solutions in Switzerland and Solnovis in Germany to ensure product supply and development.

Related Videos
Barry Eiden, OD, FAAO, FSLS, chats with Optometry Times about the 2024 IKA Symposium
R Tracy Williams, OD, FAAO, tells his favorite stories as a team optometrist for the Chicago Bulls, White Sox
R Tracy Williams, OD, FAAO, details his experience as a sports team optometrist
Andy Morgenstern, OD, FAAO, FNAP chats with Optometry Times
R Tracy Williams, OD, FAAO with Optometry Times
Shan Lin, MD, speaks on Glaucoma 360 presentation in an interview with Ophthalmology Times
Cecelia Koetting, OD, FAAO, DIPABO, left, speaks with Optometry Times about the 2024 EnVision Summit
© 2024 MJH Life Sciences

All rights reserved.